DTC Advertising: FDA To Follow The Eyeballs In Study Of Risk Perception
This article was originally published in The Pink Sheet Daily
Executive Summary
Fictional obesity product to determine how consumers perceive both superimposed text of risk information and the MedWatch statement; study cost is $299,382.
You may also be interested in...
TV Drug Advertising Study Targets Those With Limited Or No Internet Use
US FDA will assess value of including 1-800 number and print ad in broadcast commercials; it is among 42 direct-to-consumer studies the agency has undertaken, 13 of which are in progress.
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.
Legal Notebook: Catalyst’s Suit vs. FDA Is Tossed, Avonex Patent Invalidity Verdict Is Reinstated
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: